Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-β-D-ribose oxidase (DprE1) inhibitors.

In search of novel drugs against tuberculosis, we previously discovered and profiled a novel hydantoin-based family that demonstrated highly promising in vitro potency against M. tuberculosis. The compounds were found to be non-covalent inhibitors of DprE1, a subunit of decaprenylphosphoryl-β-D-ribose-2'-epimerase. This protein, localized in the periplasmic space of the mycobacterial cell wall, was shown to be an essential and vulnerable antimycobacterial drug target. Here, we report the further SAR exploration of this chemical family through more than 80 new analogues. Among these, the most active representatives combined sub-micromolar cellular potency and nanomolar target affinity with balanced physicochemical properties and low human cytotoxicity. Moreover, we demonstrate in vivo activity in an acute Mtb infection model and provide further proof of DprE1 being the target of the hydantoins. Overall, the hydantoin family of DprE1 inhibitors represents a promising non-covalent lead series for the discovery of novel antituberculosis agents.

[1]  Christophe M. L. Vande Velde,et al.  Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. , 2018, Journal of medicinal chemistry.

[2]  D. Schnappinger,et al.  Discovery and Structure–Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2′-Oxidase , 2018, Journal of medicinal chemistry.

[3]  P. Murumkar,et al.  Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. , 2018, Journal of medicinal chemistry.

[4]  Alimuddin Zumla,et al.  Accelerating the development of therapeutic strategies for drug-resistant tuberculosis , 2018, Nature Reviews Drug Discovery.

[5]  G. Besra,et al.  Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes , 2017, Angewandte Chemie.

[6]  T. Ioerger,et al.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis , 2016, Proceedings of the National Academy of Sciences.

[7]  Robert H Bates,et al.  Searching for New Leads for Tuberculosis: Design, Synthesis, and Biological Evaluation of Novel 2-Quinolin-4-yloxyacetamides. , 2016, Journal of medicinal chemistry.

[8]  S. Cole,et al.  Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase. , 2015, Bioorganic & medicinal chemistry.

[9]  G. Besra,et al.  Whole Cell Target Engagement Identifies Novel Inhibitors of Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase. , 2015, ACS infectious diseases.

[10]  M. V. Rajasekharan,et al.  Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. , 2015, European journal of medicinal chemistry.

[11]  S. Cole,et al.  DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization. , 2015, ACS chemical biology.

[12]  Maria Paola Costi,et al.  2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. , 2015, ACS chemical biology.

[13]  Christopher B. Cooper,et al.  Lead optimization of 1,4-azaindoles as antimycobacterial agents. , 2014, Journal of medicinal chemistry.

[14]  J. Mckinney,et al.  4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. , 2014, Journal of medicinal chemistry.

[15]  A. Narayan,et al.  Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. , 2014, Journal of medicinal chemistry.

[16]  Vijay T. Ahuja,et al.  Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. , 2013, Journal of medicinal chemistry.

[17]  Peter G. Schultz,et al.  University of Birmingham Identification of a small molecule with activity against drug-resistant and persistent tuberculosis , 2013 .

[18]  N. Loman,et al.  Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide and N-Benzyl-6′,7′-Dihydrospiro[Piperidine-4,4′-Thieno[3,2-c]Pyran] Analogues with Bactericidal Efficacy against Mycobacterium tuberculosis Targeting MmpL3 , 2013, PloS one.

[19]  A. Oliver,et al.  Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents. , 2013, Journal of the American Chemical Society.

[20]  Alfonso Mendoza,et al.  Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis , 2013, ChemMedChem.

[21]  Steven J Novick,et al.  Development of a high-throughput electrophysiological assay for the human ether-à-go-go related potassium channel hERG. , 2013, Journal of pharmacological and toxicological methods.

[22]  R. Read,et al.  Supplementary Materials for Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis , 2012 .

[23]  G. Besra,et al.  University of Birmingham Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors , 2012 .

[24]  S. Cole,et al.  Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1. , 2012, Journal of the American Chemical Society.

[25]  J. C. Ruble,et al.  Mild Pd-catalyzed N-arylation of methanesulfonamide and related nucleophiles: avoiding potentially genotoxic reagents and byproducts. , 2011, Organic letters.

[26]  Stewart T. Cole,et al.  Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis , 2009, Science.

[27]  H. Bucherer,et al.  Über die Bildung substituierter Hydantoine aus Aldehyden und Ketonen. Synthese von Hydantoinen , 1934 .